Literature DB >> 9216016

The impact of early lens opacity progression on visual acuity and refraction.

P Rouhiainen1, H Rouhiainen, J T Salonen.   

Abstract

The purpose of the present study was to evaluate the change in visual acuity and refraction taking place in eyes with progressing early lens opacities. Four hundred and ten hypercholesterolemic men in Eastern Finland who participated in the Kuopio Atherosclerosis Prevention Study were followed up for 3 years. Lens opacities were graded using the lens opacity classification system II (LOCS II). The change of visual acuity and refractive error from baseline to a 36-month examination was compared for different types of lens opacities. During the 3-year period, progression in the LOCS II was observed in 9.2% of the eyes for nuclear, in 4.8% for cortical and in 0.5% of the eyes for posterior subcapsular opacities. Increasing nuclear sclerosis reduced visual acuity statistically significantly both with and without correction. Hypermetropization was seen to continue in eyes with no lens opacity progression. Myopization was more common in eyes with lens opacity progression, although this was not statistically significant.

Entities:  

Mesh:

Year:  1997        PMID: 9216016     DOI: 10.1159/000310799

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  3 in total

1.  The assessment of lens opacities in clinical practice: results of a national survey.

Authors:  N A Frost; J M Sparrow
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

Review 2.  Cataract surgery with implantation of an artificial lens.

Authors:  Thomas Kohnen; Martin Baumeister; Daniel Kook; Oliver K Klaproth; Christian Ohrloff
Journal:  Dtsch Arztebl Int       Date:  2009-10-23       Impact factor: 5.594

3.  Refractive error changes in cortical, nuclear, and posterior subcapsular cataracts.

Authors:  K Pesudovs; D B Elliott
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.